Biochemical Pharmacology of Pemetrexed
PDF) The Role of Pemetrexed in Advanced Non Small-Cell Lung Cancer: Special Focus on Pharmacology and Mechanism of Action
PPT - First-Line Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) PowerPoint Presentation - ID:4546594
Pemetrexed - Wikiwand
Genetic polymorphism in ATIC is associated with effectiveness and toxicity of pemetrexed in non-small-cell lung cancer | Thorax
Figure 2 from Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. | Semantic Scholar
Pemetrexed - an overview | ScienceDirect Topics
Pemetrexed disodium, a novel antifolate with multiple targets - The Lancet Oncology
Review of a promising new agent—pemetrexed disodium - Paz‐Ares - 2003 - Cancer - Wiley Online Library
PPT - Mode of Action PowerPoint Presentation, free download - ID:3629643
Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules | British Journal of Cancer
Illustration of the similarities and differences between the cellular... | Download Scientific Diagram
Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma: Trends in Pharmacological Sciences
Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent | Future Oncology
Pemetrexed disodium | Nature Reviews Drug Discovery
Molecules | Free Full-Text | Novel Multitarget Therapies for Lung Cancer and Respiratory Disease | HTML
pemetrexed mechanism of action. | Download Scientific Diagram
Thymidylate synthase inhibitors for thoracic tumors
Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients | Pharmacogenomics
Pemetrexed in Advanced NSCLC: A Review of the Clinical Data
Folylpoly-Glutamate Synthetase Expression Is Associated with Tumor Response and Outcome from Pemetrexed-Based Chemotherapy in Malignant Pleural Mesothelioma - Journal of Thoracic Oncology
Lung-Tumorzym (LT-Zym) plus Pemetrexed (Alimta) deliver combo punch to terminal non–small cell lung cancer (NSCLC) | Herbalzym
Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity | SpringerLink
Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy | Journal for ImmunoTherapy of Cancer
Synergistic activity of combination therapy with PEGylated pemetrexed and gemcitabine for an effective cancer treatment - ScienceDirect
